CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to test whether giving acalabrutinib is safe and effective in controlling relapsed central nervous system (CNS) lymphoma...
Phase 2
Tampa, Florida, United States and 2 other locations
This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This study will consist of...
Phase 1, Phase 2
Tampa, Florida, United States and 26 other locations
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-99282 alone and in combination with anti-lymphoma...
Phase 1, Phase 2
Tampa, Florida, United States and 88 other locations
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma...
Phase 1, Phase 2
Tampa, Florida, United States and 3 other locations
purpose of this study is to assess the objective response rate of parsaclisib treatment in participants with relapsed or refractory follicular lymphoma...
Phase 2
Spring Hill, Florida, United States and 82 other locations
of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen comp...
Phase 1
Tampa, Florida, United States and 6 other locations
in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton...
Phase 2
Weeki Wachee, Florida, United States and 85 other locations
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
Phase 2
Tampa, Florida, United States and 29 other locations
with various types of blood cancers:relapsed or refractory (R/R) lymphomamultiple myelomanewly diagnosed acute myeloid leukemia (AML).This t...
Phase 1
Tampa, Florida, United States and 61 other locations
of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma...
Phase 2
Tampa, Florida, United States and 57 other locations
Clinical trials
Research sites
Resources
Legal